Hims & Hers raises $402.5m in zero-coupon notes due 2032

Hims & Hers Health (HIMS) raised $402.5 million through zero-coupon convertible senior notes due 2032, giving the telehealth company fresh financing without a cash interest bill as it pushes ahead with international expansion and AI platform spending, according to its May 21 filing. The company also used part of the proceeds to buy capped-call transactions that lift the effective dilution cap to $50.15 a share.

The notes mature on June 1, 2032 and carry a 0.00 per cent coupon, while the initial conversion price was set at $29.53 a share, the SEC filing said. That gives Hims a way to raise balance-sheet capacity at little near-term cash cost, an attractive option as investors reassess how much capital the company may need for branded weight-loss products, overseas growth and a more expensive fulfilment footprint.

Hims said in the financing announcement included in the filing that the money would support international expansion and accelerate AI-driven platform investment. The message is straightforward: management wanted growth funding now, but did not want to lock in a cash coupon while the company is still proving out a costlier phase of its strategy.

The structure matters because a convertible sits between straight debt and an equity sale. Hims gets cash upfront, delays a full dilution event and uses the capped-call overlay to offset some dilution if the shares rise above the conversion price. Shareholders still take financing risk, but the company has bought time to show that the expansion plan can support revenue growth and margins.

Why investors care now

The timing comes as Hims tries to move beyond the simpler subscription story that first won over investors. Reuters reported in March that the company was diversifying beyond compounded GLP-1 sales while expanding internationally, a shift that carries heavier working-capital needs than the earlier telehealth model. Chief executive Andrew Dudum told Reuters the business could hold up “even in a draconian scenario of compounding GLP-1s not being there,” a sign management wanted to show that growth would not rest on one category.

That case is still being tested in the market. Reuters reported on May 12 that Hims shares fell 11 per cent after the company posted a surprise quarterly loss tied to its push into branded weight-loss products and the costs that came with it. Jefferies analyst Brian Tanquilut told Reuters investors were still waiting for evidence that the company’s earnings power had stabilised.

Tanquilut said: “We view HIMS as an execution story now, but investors want to ensure that the co’s earnings power has bottomed before driving the stock much higher.”

The convert therefore reads as a bridge into a more capital-intensive stage. A company that once sold the market on asset-light telehealth economics is now using a seven-year security to fund expansion with less strain on near-term cash flow. If the strategy starts to produce steadier revenue growth and firmer margins, the 0.00 per cent coupon will look like a timely piece of financing. If execution stays uneven, the filing will stand as evidence that Hims moved early to lock in flexibility before outside funding got more expensive.